<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04455399</url>
  </required_header>
  <id_info>
    <org_study_id>20200102</org_study_id>
    <nct_id>NCT04455399</nct_id>
  </id_info>
  <brief_title>Time Efficiency Comparison of Two IntraVitreal Injection Techniques</brief_title>
  <acronym>TIVI</acronym>
  <official_title>Time Efficiency Comparison of Two Intravitreal Injection Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Eye and Laser Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Eye and Laser Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single-center, randomized, clinical trial (RCT) comparing the time efficiency&#xD;
      and safety of a single-use intravitreal injection (IVI) guide versus a traditional technique&#xD;
      using a dual blade speculum among patients undergoing IVI for various indications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single-center, randomized, clinical trial (RCT) comparing the efficiency and&#xD;
      safety of a single-use IIG with a traditional technique using a dual blade speculum among&#xD;
      patients undergoing IVI for various indications.&#xD;
&#xD;
      The investigators will include eyes of adult patients scheduled to undergo unilateral IVI for&#xD;
      neovascular age-related macular degeneration (nAMD), polypoidal choroidal vasculopathy (PCV),&#xD;
      diabetic macular edema (DME), retinal vein occlusion (RVO), choroidal neovascular membrane&#xD;
      from pathologic myopia (PM) and uveitis. The investigators will exclude eyes with a history&#xD;
      of extraocular or intraocular infection within 3 months of the scheduled IVI date, scleral&#xD;
      thinning, history of previous glaucoma surgery, history of pars plana vitrectomy,&#xD;
      hypersensitity to the IVI drug, propracaine or povidone iodine, and inability to understand&#xD;
      the informed consent form.&#xD;
&#xD;
      The eyes will be randomly assigned in 1:1 fashion into two injection arms: intravitreal&#xD;
      injection guide (IIG) and dual blade speculum (DBS). At the time of injection, a random&#xD;
      number generator will be used to generate an odd or even number for each eye. Odd eyes will&#xD;
      be assigned to IIG and even eyes will be assigned to DBS. For same day bilateral injection,&#xD;
      once the first eye is randomized to one technique, the second eye will be automatically&#xD;
      assigned to the other technique. The study will be conducted in compliance with the&#xD;
      Declaration of Helsinki. All patients will provide informed consent prior to start of study&#xD;
      procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Actual">January 9, 2021</completion_date>
  <primary_completion_date type="Actual">January 9, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intravitreal Injection Guide (Malosa, Beaver Visitec International, Waltham, MA)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of intravitreal injection procedure</measure>
    <time_frame>At time of injection procedure</time_frame>
    <description>Duration in seconds from application to removal of single-blade or dual blade speculum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>Immediately and up to 1 month after the intravitreal injection procedure</time_frame>
    <description>Frequency of adverse events and serious adverse events after intravitreal injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference for IVI technique</measure>
    <time_frame>Immediately post injection using single-blade speculum</time_frame>
    <description>Patient survey as to which technique is more comfortable and preferred among patients with prior injection experience using the dual blade speculum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Retinal Vein Occlusion With Macular Edema</condition>
  <condition>Uveitic Macular Edema</condition>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Intravitreal injection guide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single use, combination ocular surface caliper to determine point of intravitreal injection and set-depth injection guide to limit injection needle entry into the eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual blade eyelid speculum</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dual blade eyelid speculum to open eyelids followed by Castroviejo surgical caliper to measure injection point 3.5 mm from limbus</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intravitreal injection guide (Malosa)</intervention_name>
    <description>A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion</description>
    <arm_group_label>Intravitreal injection guide</arm_group_label>
    <other_name>Malosa intravitreal injection guide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dual Blade Eyelid Speculum</intervention_name>
    <description>A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.</description>
    <arm_group_label>Dual blade eyelid speculum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        * Eyes of adult patients requiring intravitreally injected medications for non-infectious&#xD;
        indications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of extraocular or intraocular infection within 3 months of the scheduled IVI&#xD;
             date&#xD;
&#xD;
          -  Scleral thinning&#xD;
&#xD;
          -  History of previous glaucoma surgery&#xD;
&#xD;
          -  History of pars plana vitrectomy&#xD;
&#xD;
          -  Hypersensitivity to the IVI drug, proparacaine or povidone iodine&#xD;
&#xD;
          -  Inability to understand the informed consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harvey S Uy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peregrine Eye and Laser Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peregrine Eye and Laser Instittute</name>
      <address>
        <city>Makati City</city>
        <state>MM</state>
        <zip>1209</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peregrine Eye and Laser Institute</investigator_affiliation>
    <investigator_full_name>Harvey Siy Uy</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>intravitreal injection</keyword>
  <keyword>intravitreal injecton guide</keyword>
  <keyword>macular edema</keyword>
  <keyword>time efficiency</keyword>
  <keyword>anti-VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

